Vycor Medical, Inc. engages in the provision of innovative surgical and therapeutic solutions to the medical community. The company is headquartered in Boca Raton, Florida and currently employs 7 full-time employees. The company went IPO on 2009-03-31. The firm designs, develops and markets neurological medical devices and therapies. The firm operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Vycor Medical designs, develops and markets medical devices for use in neurosurgery. NovaVision provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage, such as that caused by a stroke. Vycor Medical’s ViewSite Brain Access System (VBAS) is a next-generation retraction and access system. VBAS is a minimally invasive neurosurgical device designed to improve access to brain lesions while reducing tissue damage and enhancing patient outcomes. The VBAS system is used in over 300 hospitals in the United States and in numerous countries internationally. NovaVision products include Visual Restoration Therapy (VRT) and NeuroEyeCoach.
VYCO stock price ended at $0.14 on 星期五, after rising 0.00%
On the latest trading day Jan 16, 2026, the stock price of VYCO rose by 0.00%, climbing from $0.14 to $0.14. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.14 and a high of $0.14. Notably, trading volume dropped by 2.8K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 5.0K shares were traded, equating to a market value of approximately $4.6M.